Federal funding will fuel new innovations combining basic science and clinical care; brings total support to $140 million since institute opened in 2010
UC San Diego scientists have launched a clinical trial to investigate whether a drug approved for treating high blood pressure might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.
ACE inhibitor drugs like Ramipril are widely used for various cardiovascular conditions; researchers want to see if they might also provide benefit to patients infected by SARS-CoV-2
UC San Diego Health has launched a Phase III clinical trial to assess whether a medication used to treat rheumatoid might also have therapeutic value for patient with COVID-19 who have developed or are at high risk of developing serious lung damage from SARS-CoV-2 infections.
Clinical trials at UC San Diego Health and elsewhere will assess whether tocilizumab can reduce out-of-control inflammation that damages lungs and increases risks for ventilation and death
Researchers at UC San Diego Health report in newly published findings that olfactory impairment suggests the resulting COVID-19 disease is more likely to be mild to moderate, a potential early indicator that could help health care providers determine which patients may require hospitalization.
Health Media Contacts
Find the best contact for health-related media inquiries.
